Home » Stocks » Epizyme

Epizyme, Inc. (EPZM)

Stock Price: $13.32 USD -0.25 (-1.84%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $13.30 -0.02 (-0.15%) Oct 23, 6:58 PM

Stock Price Chart

Key Info

Market Cap 1.35B
Revenue (ttm) 13.83M
Net Income (ttm) -201.88M
Shares Out 101.48M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $13.32
Previous Close $13.57
Change ($) -0.25
Change (%) -1.84%
Day's Open 13.70
Day's Range 13.13 - 13.81
Day's Volume 824,713
52-Week Range 10.51 - 27.82

More Stats

Market Cap 1.35B
Enterprise Value 1.12B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 101.48M
Float 87.23M
EPS (basic) -2.09
EPS (diluted) -2.00
FCF / Share -2.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.38M
Short Ratio 11.07
Short % of Float 11.90%
Beta 1.80
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 97.74
PB Ratio 5.35
Revenue 13.83M
Operating Income -204.36M
Net Income -201.88M
Free Cash Flow -235.14M
Net Cash 232.03M
Net Cash / Share 2.29
Gross Margin -786.92%
Operating Margin -1,477.67%
Profit Margin -1,459.70%
FCF Margin -1,700.25%
ROA -31.98%
ROE -65.22%
ROIC -71.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$27.62*
(107.36% upside)
Low
16.0
Current: $13.32
High
36.0
Target: 27.62
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue23.8021.7010.008.012.5641.4168.4845.226.94
Revenue Growth9.68%117%24.89%212.77%-93.82%-39.53%51.44%551.24%-
Gross Profit23.8021.7010.008.012.5641.4168.4845.226.94
Operating Income-177-128-137-112-133-55.05-3.13-0.77-20.97
Net Income-170-124-134-110-132-55.01-3.48-0.70-20.96
Shares Outstanding89.8971.8661.4757.1339.8433.0317.051.651.43
Earnings Per Share-1.93-1.72-2.18-1.93-3.32-1.67-0.22-0.72-14.65
Operating Cash Flow-147-122-120-96.37-72.93-35.36-53.7344.1510.00
Capital Expenditures-0.59-0.30-0.98-0.62-0.18-2.22-0.63-1.48-0.92
Free Cash Flow-148-122-121-97.00-73.11-37.58-54.3642.679.08
Cash & Equivalents38124027624220819012497.9833.34
Total Debt45.47-0.110.731.29----
Net Cash / Debt33624027624120719012497.9833.34
Assets42527628925221819916310437.36
Liabilities93.4542.4953.9950.7448.3738.9258.6815588.00
Book Value331233235202170160104-51.13-50.64
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Epizyme, Inc.
Country United States
Employees 203
CEO Robert B. Bazemore

Stock Information

Ticker Symbol EPZM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: EPZM
IPO Date May 31, 2013

Description

Epizyme, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.